Stratagene and Merck Subsidiary, Rosetta Inpharmatics, Enter into Joint Development and License Agreement; Companies Will Devel
August 14 2006 - 6:30AM
Business Wire
Stratagene Corporation (Nasdaq:STGN), a developer, manufacturer and
marketer of specialized life science research and diagnostics
products, announced today that it has entered into a joint
development and license agreement with Rosetta Inpharmatics LLC, a
wholly-owned subsidiary of Merck & Co., Inc., to create an
automated solution for the isolation of nucleic acids from a
variety of clinical samples. Nucleic acid purification allows
researchers to separate RNA contained in biological samples.
Clinicians and researchers can use the purified RNA to perform gene
expression analysis and other functions within molecular
diagnostics. Under the terms of the agreement, Stratagene and
Rosetta will jointly develop a proprietary instrument and a
single-use consumable that will be manufactured and commercialized
by Stratagene. These products will be sold to Stratagene's current
customer base and companies engaged in pharmacogenomics. Financial
terms of the agreement were not disclosed. "This agreement with
Rosetta Inpharmatics is a significant opportunity for Stratagene
and marks another milestone in our molecular diagnostics strategy,"
said Joseph A. Sorge, MD, President and CEO of Stratagene. "We
believe we have a unique opportunity to create and introduce a
differentiated product that will automate the RNA purification
process and provide consistent, reproducible results. These two
characteristics are critical capabilities in gene expression
analysis." About Stratagene Corporation Stratagene is a developer,
manufacturer and marketer of specialized life science research and
diagnostic products. The Company's life science research unit
supports advances in science by inventing, manufacturing and
distributing products that simplify, accelerate and improve
research. These products are used throughout the academic,
industrial and government research sectors in fields spanning
molecular biology, genomics, proteomics, drug discovery and
toxicology. The Company's diagnostic unit develops and manufactures
products for urinalysis as well as high quality automated
instrument and reagent systems that use blood samples to test for
more than 1,000 different allergies and autoimmune disorders. In
addition, by combining its expertise in diagnostics and molecular
biology, as well as its experience with FDA regulatory procedures,
the Company is pursuing opportunities to expand its product
portfolio to include molecular diagnostic kits and instrumentation.
More information is available at www.stratagene.com. Safe Harbor
Statement Certain statements in this news release that are not
historical fact constitute "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
Stockholders and other readers are cautioned not to place undue
reliance on these forward-looking statements. Stratagene generally
identifies forward-looking statements by using words like
"believe," "intend," "target," "expect," "estimate," "may,"
"should," "plan," "project," "contemplate," "anticipate," "predict"
or similar expressions. You can also identify forward-looking
statements by discussions of strategies, plans or intentions. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors, which may cause the actual results
of Stratagene to be materially different from historical results or
from any results expressed or implied by such forward-looking
statements. Among the important factors that could cause actual
results to differ materially from those contained in or implied by
the forward-looking statements are risks associated with the
company's inability to sufficiently anticipate market needs and
develop products and product enhancements that achieve market
acceptance, the company's ability to compete effectively in the
diagnostics and life science research markets, variability of the
company's quarterly revenues and operating results, the failure of
the company to retain key employees, the company's ability to
obtain additional debt or equity financing, the possibility of
declining sales due in part to a reduction in research and
development budgets or government funding, the company's ongoing
ability to protect its own intellectual property rights and to
avoid violating the intellectual property rights of third parties,
extended manufacturing difficulties and currency fluctuations. For
more information about these and other factors that could cause
actual results to differ materially from those contained in or
implied by the forward-looking statements please see Item "1A. Risk
Factors" included in Stratagene's Annual Report on Form 10-K for
the year ended December 31, 2005 and in other reports filed by
Stratagene from time to time with the Securities and Exchange
Commission, including Quarterly Reports on Form 10-Q.
Stratagene (NASDAQ:STGN)
Historical Stock Chart
From Sep 2024 to Oct 2024
Stratagene (NASDAQ:STGN)
Historical Stock Chart
From Oct 2023 to Oct 2024